Skip to main content
. 2022 Feb 13;17(2):153–176. doi: 10.1016/j.ajps.2022.02.001

Table 5.

List of nanomedicines approved or under clinical investigation for the treatment of RDs.

RD Status Nanomedicine Product name Molecule NCT ID
AMD Approved by FDA Liposome Visudyne® Verteporfin NCT00121407
wAMD Approved by FDA Aptamer–polymer nanoparticle Macugen® Pegaptanib sodium NCT00549055
Macular edema Approved by FDA Suspension Kenalog Triamcinolone acetonide NCT00101764
Phase II Lipid-based nanoparticle TLC399 (ProDex) Dexamethasone sodium phosphate NCT03093701